Dr. Mohamed M. Hegazi
Claim this profileThe James Graham Brown Cancer Center at University of Louisville
Studies Lymphoma
Studies Leukemia
10 reported clinical trials
33 drugs studied
Area of expertise
1Lymphoma
Stage I
Stage II
CCND1 positive
2Leukemia
BCR-ABL1 positive
FLT3 positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Mohamed M. Hegazi is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
More about Mohamed M. Hegazi
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Mohamed M. Hegazi has experience with
- Cytarabine
- Azacitidine
- Venetoclax
- Autologous Hematopoietic Stem Cell Transplantation
- Dexamethasone
- Lenalidomide
Breakdown of trials Mohamed M. Hegazi has run
Lymphoma
Leukemia
Acute Myeloid Leukemia
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mohamed M. Hegazi specialize in?
Mohamed M. Hegazi focuses on Lymphoma and Leukemia. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage II.
Is Mohamed M. Hegazi currently recruiting for clinical trials?
Yes, Mohamed M. Hegazi is currently recruiting for 9 clinical trials in Louisville Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Mohamed M. Hegazi has studied deeply?
Yes, Mohamed M. Hegazi has studied treatments such as Cytarabine, Azacitidine, Venetoclax.
What is the best way to schedule an appointment with Mohamed M. Hegazi?
Apply for one of the trials that Mohamed M. Hegazi is conducting.
What is the office address of Mohamed M. Hegazi?
The office of Mohamed M. Hegazi is located at: The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky 40202 United States. This is the address for their practice at the The James Graham Brown Cancer Center at University of Louisville.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.